Polycythemia Global Market Report 2026

Polycythemia refers to a blood disorder in which the body generates an abnormally elevated number of red blood cells, leading to increased blood viscosity and reduced efficiency of blood flow. This disorder can result in complications such as blood clots, strokes, and cardiovascular issues, and it may arise as a primary bone marrow condition or secondarily due to low oxygen levels or other underlying medical problems.

The major types of polycythemia include primary polycythemia, secondary polycythemia, and pseudopolycythemia. Primary polycythemia is a blood disorder marked by the overproduction of red blood cells due to intrinsic bone marrow abnormalities. Treatments are classified by drug classes, including antimetabolites, Janus kinase 2 inhibitors, myelosuppressive agents, selective serotonin reuptake inhibitors, folic acid, and other categories, administered through oral, intravenous, and intramuscular routes. End users include hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs are influencing the polycythemia market by increasing the import cost of active pharmaceutical ingredients, biologic injectables, and hematology diagnostic kits used across treatment workflows. These duties are raising production and procurement expenses for manufacturers that depend on cross border sourcing of drug compounds and medical consumables. Drug classes such as jak inhibitors and interferon products are more exposed due to complex global supply chains. North america and parts of europe face stronger impact where specialty drugs are frequently imported. Smaller suppliers and hospital procurement networks are experiencing margin pressure and slower purchasing cycles. At the same time, tariff barriers are encouraging domestic manufacturing of hematology drugs and phlebotomy kits. This is supporting local suppliers and improving regional supply chain stability.

The polycythemia market research report is one of a series of new reports from The Business Research Company that provides polycythemia market statistics, including polycythemia industry global market size, regional shares, competitors with a polycythemia market share, detailed polycythemia market segments, market trends and opportunities, and any further data you may need to thrive in the polycythemia industry. This polycythemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The polycythemia market size has grown strongly in recent years. It will grow from $4.68 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of myeloproliferative disorders, increasing awareness of rare blood diseases, expansion of specialty hematology centers, higher diagnostic testing rates, growth in use of cytoreductive drugs.

The polycythemia market size is expected to see strong growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to advancements in targeted JAK2 therapies, increasing genetic screening adoption, rising demand for personalized treatment plans, expanding access to specialty biologics, growing elderly population base. Major trends in the forecast period include growing adoption of janus kinase inhibitors, rising use of interferon based injectable therapies, increasing preference for therapeutic phlebotomy procedures, expansion of hematocrit monitoring diagnostics, shift toward combination drug therapy approaches.

The increasing prevalence of myeloproliferative diseases is expected to drive the growth of the polycythemia market in the coming years. Myeloproliferative diseases encompass a group of rare blood disorders marked by the abnormal overproduction of blood cells in the bone marrow, impairing blood function and circulation. The rising occurrence of age-related hematological abnormalities is a major contributor to the increased prevalence of these disorders, as older populations are more vulnerable to bone marrow dysfunction. Polycythemia, a significant subtype of myeloproliferative diseases characterized by excessive red blood cell production, plays a crucial role in enhancing clinical awareness, diagnosis, and ongoing monitoring of these conditions, thereby supporting market growth. For instance, in September 2024, according to Blood Cancer United, a US-based nonprofit organization focused on curing blood cancers, over 120,000 people in the United States were estimated to be living with or in remission from myeloproliferative neoplasms (MPNs) in 2023, indicating a rising prevalence of these chronic hematologic disorders. Therefore, the growing incidence of myeloproliferative diseases is driving the polycythemia market.

Key companies operating in the polycythemia market are focusing on advanced innovations such as rusfertide, a first-in-class hepcidin mimetic peptide, which significantly reduces the need for frequent phlebotomies while improving hematocrit control and patient quality of life. A hepcidin mimetic is a drug or compound designed to act like hepcidin, the body's main hormone that regulates iron balance. For example, in March 2025, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, announced positive topline results from the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera, demonstrating significant reduction in phlebotomy dependence, improved hematocrit control, and meaningful patient-reported outcomes, while maintaining a favorable safety profile.

In March 2025, Ono Pharmaceutical, a Japan-based pharmaceutical company, partnered with Ionis Pharmaceuticals to advance the development, regulatory approval, and global commercialization of sapablursen, a novel RNA-targeted therapy for polycythemia vera, leveraging Ionis Pharmaceuticals' expertise to address unmet needs in rare blood disorders. Ionis Pharmaceuticals is a US-based company specializing in RNA-targeted therapies for rare blood disorders, including treatments for polycythemia.

Major companies operating in the polycythemia market are Bristol Myers Squibb Company, Roche Holding AG, Merck And Company Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, Ionis Pharmaceuticals Inc., CTI BioPharma Corp., AOP Orphan Pharmaceuticals AG, Silence Therapeutics Plc, Italfarmaco S.p.A., PharmaEssentia Corporation, Karyopharm Therapeutics Inc., Protagonist Therapeutics Inc., Kartos Therapeutics Inc., Geron Corporation, and Perseus Proteomics Inc.

North America was the largest region in the polycythemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polycythemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the polycythemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polycythemia market consists of sales of therapeutic phlebotomy kits, cytoreductive drug formulations, antiplatelet medication products, janus kinase inhibitor drugs, interferon-based injectable products, and hematocrit monitoring test kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polycythemia Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses polycythemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for polycythemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The polycythemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Primary polycythemia; Secondary polycythemia; Pseudopolycythemia
• 2) By Drug Class: Antimetabolites; Janus Kinase 2 Inhibitors; Myelosuppressive Agents; Selective Serotonin Reuptake Inhibitors; Folic Acid; Other Drug Classes
• 3) By Route Of Administration: Oral; Intravenous; Intramuscular
• 4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Primary Polycythemia: Polycythemia Vera; Familial Primary Polycythemia
• 2) By Secondary Polycythemia: Hypoxia Induced Polycythemia; Tumor Associated Polycythemia; Drug Induced Polycythemia; Hormone Induced Polycythemia
• 3) By Pseudopolycythemia: Stress Related Polycythemia; Dehydration Related Polycythemia; Plasma Volume Contraction Related Polycythemia
• Companies Mentioned: Bristol Myers Squibb Company; Roche Holding AG; Merck And Company Inc.; Bayer AG; Novartis AG; Takeda Pharmaceutical Company; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Incyte Corporation; Ionis Pharmaceuticals Inc.; CTI BioPharma Corp.; AOP Orphan Pharmaceuticals AG; Silence Therapeutics Plc; Italfarmaco S.p.A.; PharmaEssentia Corporation; Karyopharm Therapeutics Inc.; Protagonist Therapeutics Inc.; Kartos Therapeutics Inc.; Geron Corporation; and Perseus Proteomics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.